All In Biotech

Drug Trial Radar · NCT05215418

A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects

A Multicenter, Randomized, Double-Blind Study to Compare the Effects of VI-0521,Phentermine, and Placebo on Ambulatory Blood Pressure in Overweight or Obese Subjects

Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 565 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

565

Actual

Start

Jan 25, 2022

Primary completion

Apr 11, 2023

Study completion Apr 17, 2023

Sponsor

Lead sponsor
VIVUS LLCIndustry
Sponsor type
Industry
First posted
Jan 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).

Conditions

  • Blood Pressure

Interventions

  • VI-0521Drug

    Phentermine/Topiramate Top Dose 15 mg/92 mg capsule

  • PhentermineDrug

    Phentermine 30 mg capsule

  • PlaceboDrug

    Inactive oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 8 in Mean Systolic Blood Pressure as Measured by 24-hr ABPMTime frame: Baseline to Week 8

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Site

    Anniston, Alabama

  • Clinical Site

    Mobile, Alabama

  • Clinical Site

    Lincoln, California

  • Clinical Site

    Long Beach, California

  • Clinical Site

    Sacramento, California

  • Clinical Site

    Spring Valley, California

  • Clinical Site

    Upland, California

  • Clinical Site

    Washington D.C., District of Columbia

  • Clinical Site

    Coral Gables, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Port Orange, Florida

  • Clinical Site

    Brownsburg, Indiana

  • Clinical Site

    Evansville, Indiana

  • Clinical Site

    Wichita, Kansas

  • Clinical Site

    Lexington, Kentucky

  • Clinical Site

    Louisville, Kentucky

  • Clinical Site

    Baton Rouge, Louisiana

  • Clinical Site

    Kansas City, Missouri

  • Clinical Site

    Butte, Montana

  • Clinical Site

    Cary, North Carolina

  • Clinical Site

    Eugene, Oregon

  • Clinical Site

    Columbia, South Carolina

  • Clinical Site

    Knoxville, Tennessee

  • Clinical Site

    Friendswood, Texas

  • Clinical Site

    North Richland Hills, Texas

  • Clinical Site

    San Antonio, Texas

  • Clinical site

    Salt Lake City, Utah

  • Clinical Site

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.